Raymond James initiates coverage on Tvardi Therapeutics stock with Outperform rating

Investing.com - Raymond (NSE:RYMD) James initiated coverage on Tvardi Therapeutics Inc (NASDAQ:TVRD) with an Outperform rating and a price target of $62.00 on Monday. The stock, currently trading at $27.34, has shown remarkable momentum with a 27% gain in the past week, according to InvestingPro data.

The research firm highlighted Tvardi’s development of TTI-101, an oral small molecule inhibitor targeting STAT3, a central signaling molecule associated with fibrosis and cancer development.

Raymond James noted that in Tvardi’s Phase 2 idiopathic pulmonary fibrosis (IPF) program, TTI-101 aims to slow, potentially halt, or reverse fibrosis in a rare disease with a 3-5 year post-diagnosis survival rate, addressing an area where existing treatments leave room for improvement.

The firm pointed to Tvardi’s hepatocellular cancer (HCC) program, where initial tumor response data for TTI-101 appears competitive with current treatment options for this common liver cancer.

Raymond James expressed confidence that TTI-101’s demonstrated clinical efficacy and safety profile have significantly derisked Tvardi’s IPF and HCC programs, despite historical challenges with STAT3 inhibition therapies.

In other recent news, Tvardi Therapeutics has been the focus of several analyst firms with their coverage highlighting the company’s developments. Tvardi recently completed enrollment for its Phase 2 trial of TTI-101 for treating idiopathic pulmonary fibrosis (IPF), with data expected in the fourth quarter of 2025. BTIG maintains a Buy rating with a $55 price target, emphasizing the potential of TTI-101 to reverse disease progression in IPF, a market valued at approximately $5 billion. Cantor Fitzgerald initiated coverage with an Overweight rating and a $52 price target, focusing on the potential for TTI-101 to treat not only IPF but other fibrotic diseases. Piper Sandler also initiated coverage with an Overweight rating and a $78 price target, noting Tvardi’s recent reverse merger with Cara Therapeutics and its cash runway into the second half of 2026. Oppenheimer issued an Outperform rating with a $65 price target, highlighting TTI-101’s potential in both IPF and hepatocellular carcinoma, with peak risk-adjusted sales projected at $1.2 billion by 2040. The analysts’ coverage reflects a positive outlook on Tvardi’s financial stability and its ability to reach key developmental milestones.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.